Advench Pharmaceutical Private Limited

Olimab Injection is a medication primarily used for the treatment and prevention of osteoporosis in postmenopausal women and men at increased risk of fractures. It contains Denosumab, a monoclonal antibody that works by inhibiting a protein called RANK ligand (RANKL). This protein plays a crucial role in the formation and activity of osteoclasts—the cells responsible for bone resorption. By blocking RANKL, Denosumab reduces bone breakdown, increases bone mineral density, and lowers the risk of fractures. Olimab is typically administered as a subcutaneous injection of 60 mg once every six months by healthcare professionals, usually in the upper arm, thigh, or abdomen. This administration schedule supports long-lasting effects to strengthen bones and prevent fractures. The injection comes in a pre-filled syringe of 1 ml containing 60 mg of Denosumab. It should be stored refrigerated between 2°C to 8°C and protected from freezing and light to maintain potency. Common side effects include rash, musculoskeletal pain, nerve pain, constipation, headache, upper respiratory infections, and joint pain. Patients are advised to take adequate calcium and vitamin D supplements during treatment to support bone health. Use with caution in individuals with certain medical conditions, and administration should be supervised by healthcare professionals to monitor for any adverse reactions. Olimab is effective in managing osteoporosis by slowing bone loss and helping maintain bone strength, making it a valuable treatment for patients at high risk of fractures.